Suzhou Ribo Life Science Co., Ltd. (HKG:6938)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Biotechnology (Startups)	148.51M	142.63M	44.00K	-	-
Total	148.51M	142.63M	44.00K	-	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Overseas	105.41M	101.05M	-	-	-
Mainland China	43.10M	41.58M	44.00K	-	-
Total	148.51M	142.63M	44.00K	-	-

Data Source: S&P Global Market Intelligence Last updated: Aug 27, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Sep 9, 2026

Data Sources Report a data error